Reference : Regulation of N6-Methyladenosine after Myocardial Infarction
Scientific journals : Article
Life sciences : Multidisciplinary, general & others
Regulation of N6-Methyladenosine after Myocardial Infarction
Vausort, Mélanie [> >]
Niedolistek, Magdalena [> >]
Lumley, Andrew I. [> >]
Oknińska, Marta [> >]
Paterek, Aleksandra [> >]
Mączewski, Michał [> >]
Dong, Xiangyi mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Enzymology and Metabolism]
Jäger, Christian mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Scientific Central Services]
Linster, Carole mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Enzymology and Metabolism]
Leszek, Przemyslaw [> >]
Devaux, Yvan mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) >]
[en] m6A ; RNA methylation ; Myocardial infarction ; heart failure ; biomarker
[en] Development of heart failure (HF) after myocardial infarction (MI) is responsible for premature death. Complex cellular and molecular mechanisms are involved in this process. A number of studies have linked the epitranscriptomic RNA modification N6-methyladenosine (m6A) with HF, but it remains unknown how m6A affects the risk of developing HF after MI. We addressed the regulation of m6A and its demethylase fat mass and obesity-associated (FTO) after MI and their association with HF. Using liquid chromatography coupled to mass spectrometry, we observed an increase of m6A content in the infarcted area of rat hearts subjected to coronary ligation and a decrease in blood. FTO expression measured by quantitative PCR was downregulated in the infarcted hearts. In whole blood samples collected at the time of reperfusion in MI patients, m6A content was lower in patients who developed HF as attested by a 4-month ejection fraction (EF) of ≤40 as compared to patients who did not develop HF (EF \textgreater 50\%). M6A content was higher in females. These results show that m6A measured in blood is associated with HF development after MI and motivate further investigation of the potential role of m6A as a novel epitranscriptomics biomarker and therapeutic target of HF.

File(s) associated to this reference

Fulltext file(s):

Open access
cells-11-02271.pdfPublisher postprint1.9 MBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.